BioLineRx (NASDAQ:BLRX) Stock Passes Above Two Hundred Day Moving Average – What’s Next?

BioLineRx Ltd. (NASDAQ:BLRX)’s share price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $3.76 and traded as high as $3.89. BioLineRx shares last traded at $3.87, with a volume of 15,252 shares traded.

Analysts Set New Price Targets

Several analysts have recently commented on the company. HC Wainwright reaffirmed a “buy” rating on shares of BioLineRx in a research report on Tuesday, June 17th. Wall Street Zen raised BioLineRx to a “sell” rating in a research report on Saturday, July 12th. Finally, Jones Trading raised BioLineRx from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 30th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Strong Buy” and an average target price of $26.00.

BioLineRx Trading Up 2.9%

The company has a debt-to-equity ratio of 0.33, a current ratio of 2.06 and a quick ratio of 1.87. The company has a fifty day moving average of $3.96 and a 200-day moving average of $3.76. The firm has a market capitalization of $16.49 million, a PE ratio of -0.44 and a beta of 1.26.

BioLineRx (NASDAQ:BLRX) last announced its quarterly earnings data on Thursday, August 14th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.65). BioLineRx had a negative return on equity of 49.74% and a negative net margin of 45.34%.The firm had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $0.66 million. On average, sell-side analysts anticipate that BioLineRx Ltd. will post -5.8 earnings per share for the current fiscal year.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.